PLMA_1170x120_7-2-21

Stiolto Respimat Inhalation Spray

Boehringer Ingelheim COPD treatment gets FDA approval

Boehringer Ingelheim COPD treatment gets FDA approval

RIDGEFIELD, Conn. — Boehringer Ingelheim has received approval from the Food and Drug Administration for Stiolto Respimat Inhalation Spray, a medication for chronic obstructive pulmonary disease (COPD). The company said Tuesday that Stiolto Respimat Inhalation Spray (tiotropium bromide and olodaterol) was approved as a long-term, once-daily maintenance treatment for airflow obstruction in patients with COPD,